Eisai Stock Drops After Alzheimer’s Drug Lecanemab Fails to Get EU Approval
Eisai's shares plummeted 12% after their Alzheimer's drug, lecanemab, failed to secure European Union approval due to concerns over...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Eisai's shares plummeted 12% after their Alzheimer's drug, lecanemab, failed to secure European Union approval due to concerns over...
In a surprising turn of events, the European Medicines Agency's Committee for Medicinal Products for Human Use rejected marketing...
Biogen Inc.'s stock plunged over 6% premarket after European regulators rejected their Alzheimer's disease treatment, Leqembi, jointly marketed with...
A new Alzheimer's disease treatment by Eli Lilly received positive feedback from the FDA's advisers, increasing hopes for approval....
Biogen Inc. reported fourth-quarter results that fell short of expectations, with declining multiple-sclerosis product sales offsetting the uptake of...
Merck's cancer treatment Keytruda, in combination with Eisai's drug Lenvima, failed to meet its primary goals in a late-stage...
Merck & Co. and Eisai announced that a late-stage study of their cancer drugs Keytruda and Lenvima as a...
Biogen Inc. and Eisai Co. have released new data on their Alzheimer's treatment Leqembi, showing that a weekly subcutaneous...